Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 18:2022:2524156.
doi: 10.1155/2022/2524156. eCollection 2022.

LINC00460 Stimulates the Proliferation of Vascular Endothelial Cells by Downregulating miRNA-24-3p

Ruofei Jia  1 , Xingxing Yuan  2 , Chengzhi Yang  1 , Jing Han  1 , Xiaojing Cao  1 , Zheng Qin  1 , Jing Nan  1 , Zening Jin  1
Affiliations

LINC00460 Stimulates the Proliferation of Vascular Endothelial Cells by Downregulating miRNA-24-3p

Ruofei Jia et al. Dis Markers. .

Abstract

Objective: To clarify the effect of LINC00460 on mediating the proliferative ability of vascular endothelial cells (ECs) by targeting microRNA-24-3p (miRNA-24-3p), thus influencing the progression of atherosclerotic diseases.

Methods: Relative levels of LINC00460 and miRNA-24-3p in ECs induced with different doses of ox-LDL (oxidized low density lipoprotein) for different time points were determined by quantitative real-time polymerase chain reaction (qRT-PCR). Influences of LINC00460 and miRNA-24-3p on the viability of ECs were assessed by Cell Counting Kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) assay. Through dual-luciferase reporter gene assay, the binding between LINC00460 and miRNA-24-3p was evaluated. At last, rescue experiments were performed to identify the function of the LINC00460/miRNA-24-3p axis in regulating the proliferative ability of ECs.

Results: LINC00460 was upregulated after ox-LDL treatment in a dose- and time-dependent manner. Viability of ECs gradually increased with the prolongation of ox-LDL treatment and the treatment of increased dose. The overexpression of LINC00460 enhanced the viability and EdU-positive rate in ECs treated with ox-LDL. miRNA-24-3p was the direct target of LINC00460, which was negatively regulated by LINC00460. miRNA-24-3p was downregulated with the prolongation of ox-LDL treatment. The overexpression of miRNA-24-3p could reverse the effect of LINC00460 on regulating the proliferative ability of ECs.

Conclusions: LINC00460 regulates the proliferative ability of ECs and thus the occurrence and development of coronary atherosclerotic diseases by targeting miRNA-24-3p.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflict of interest.

Figures

Figure 1
Figure 1
LINC00460 was upregulated after ox-LDL treatment. (a) CCK-8 assay showed the viability in ECs treated with 0, 1, 10, and 100 μg/mL ox-LDL for 24 h. (b) CCK-8 assay showed the viability in ECs treated with 100 μg/mL ox-LDL for 0, 24, 48, and 72 h. (c) Relative level of LINC00460 in ECs treated with 0, 1, 10, and 100 μg/mL ox-LDL for 24 h. (d) Relative level of LINC00460 in ECs treated with 100 μg/mL ox-LDL for 0, 24, 48, and 72 h.
Figure 2
Figure 2
The overexpression of LINC00460 accelerated the proliferative ability of ECs. (a) Transfection efficacy of pcDNA-LINC00460 in ECs. (b) CCK-8 assay showed the viability in ECs transfected with pcDNA-NC or pcDNA-LINC00460. (c) DAPI-labeled, EdU-labeled, and merged images of ECs transfected with pcDNA-NC or pcDNA-LINC00460.
Figure 3
Figure 3
LINC00460 bound to miR-24-3p. (a) Relative levels of miRNA-24-3p, miRNA-485-5p, miRNA-149-5p, miRNA-662, and miRNA-671-5p in ECs transfected with pcDNA-NC or pcDNA-LINC00460. (b) MiR-24-3p level in ECs treated with 100 μg/mL ox-LDL for 0, 24, 48, and 72 h. (c) Binding sites in promoter regions of LINC00460 and miR-24-3p. (d) Luciferase activity in ECs after cotransfection with miR-24-3p mimic/negative control and LINC00460-WT/LINC00460-MT, respectively. (e) Transfection efficacies of miR-24-3p mimics and miR-24-3p inhibitor. (f) LINC00460 level in ECs transfected with NC, miR-24-3p mimics, or miR-24-3p inhibitor.
Figure 4
Figure 4
The overexpression of miR-24-3p reversed the role of LINC00460 on EC proliferation. ECs were transfected with pcDNA-NC, pcDNA-LINC00460 + miR-24-3p control, or pcDNA-LINC00460 + miR-24-3p mimics. (a) CCK-8 assay showed the viability. (b) DAPI-labeled, EdU-labeled, and merged images of ECs.
See this image and copyright information in PMC

References

    1. Leong D. P., Joseph P. G., McKee M., et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circulation Research . 2017;121(6):695–710. - PubMed
    1. Jokinen E. Obesity and cardiovascular disease. Minerva Pediatrica . 2015;67(1):25–32. - PubMed
    1. Aggarwal M., Aggarwal B., Rao J. Integrative medicine for cardiovascular disease and prevention. The Medical Clinics of North America . 2017;101(5):895–923. - PubMed
    1. Berinstein E., Levy A. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opinion on Drug Metabolism & Toxicology . 2017;13(9):973–983. - PubMed
    1. Yamagata K. Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease. Lipids in Health and Disease . 2017;16(1):p. 118. doi: 10.1186/s12944-017-0514-6. - DOI - PMC - PubMed

LinkOut - more resources